Pharma stocks delivered exceptional performance on Monday, with the sector rallying 2% despite challenging market conditions. According to Business Standard, the Nifty Pharma index surged 2% on the National Stock Exchange (NSE) in an otherwise weak market, with the index hitting an intra-day high of 26,126.20 points. The strong buying momentum across the pharmaceutical sector lifted the sectoral benchmark index, demonstrating resilience against broader market weakness. The rally came as investors focused on defensive sectors amid higher demand opportunity and Indian rupee weakness tailwinds. As per ET Now, the Nifty Pharma index climbed 358.15 points, or 1.40 per cent, to close at 26,003.15 on Monday, July 21, reflecting broad-based buying interest across pharmaceutical stocks.
Torrent Pharmaceuticals, Mankind Pharma, Cipla, Laurus Labs, Aurobindo Pharma, Wockhardt, Sai Life Sciences, Alkem Laboratories, Divis Laboratories, Lupin and Dr Reddy's Laboratories were up in the range of 2% to 5% on the NSE in intra-day deals, as reported by Business Standard. RPG Life Sciences, Thyrocare Technologies, Hester Biosciences, Rubicon Research, IOL Chemicals & Pharmaceuticals, Emcure Pharmaceuticals, Themis Medicare and Suven Life Sciences from the BSE Healthcare index rallied between 4% and 8%. The sector's strong performance was further enhanced by Natco Pharma's regulatory approval and defensive positioning amid market volatility. According to ET Now, Glenmark Pharmaceuticals leads with an estimated upside potential of 15.01 per cent, followed by Alkem Laboratories at 7.57 per cent, Mankind Pharma at 6.89 per cent, Aurobindo Pharma at 4.45 per cent, Cipla at 4.06 per cent, Sun Pharma at 6.58 per cent, Lupin at 1.48 per cent, and Glenmark has delivered the highest three-year return at 201.83 per cent among the selected pharma stocks.
Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZeneca's Lynparza. As reported by The Economic Times, this approval addresses a $1.4-billion U.S. market opportunity for the cancer drug. The company will manufacture the product, while Alembic Pharmaceuticals will handle its U.S. commercialisation. The commercial launch depends on ongoing litigation, marking a significant regulatory milestone for the pharmaceutical sector.
Emcure Pharma received a 'Buy' rating from Motilal Oswal Financial Services with a target price of ₹2,260, as reported by Business Standard. The brokerage expects the domestic business to sustain an 11% sales compound annual growth rate (CAGR) over FY26-28E, reaching revenue of ₹4,900 crore by FY28E. Analysts project a CAGR of 14%/20%/28% in revenue/EBITDA/PAT over FY26-28 to ₹11,900 crore/₹2,600 crore/₹1,450 crore respectively. The diversified earnings base with a 20% average RoE over FY26-28 leads to an industry-level PE multiple of 28x, supporting the positive outlook.
The pharmaceutical sector's outperformance came against the backdrop of a weaker Indian stock market, with the NIFTY50 index down 0.35% during afternoon trading. As reported by INVAsset PMS, investors are shifting to defensive sector bets due to crude oil prices rising above $91 per barrel, divided expectations of a rate hike from the US Federal Reserve, and the Q1 earnings season impact. Rupee weakness adds a translation tailwind for export-heavy names, particularly benefiting companies with significant US market exposure. According to ET Now, pharmaceutical stocks have remained in focus amid resilient domestic demand, export opportunities and continued product launches, with several companies retaining favourable analyst recommendations. The global macro environment remains dynamic amid geopolitical conflicts and changing trade relations, while the Indian pharmaceuticals market expanded by 8.6% over the last year.
Market experts predict the Indian pharma sector will witness a stronger footing than several other sectors despite margin pressures due to higher input costs and pricing dynamics in the US market. According to RPG Life Sciences, the outlook remains encouraging with rising healthcare awareness, expanding access to quality treatment, continuous innovation, improving healthcare infrastructure and a growing focus on chronic disease management providing a sturdy foundation for long-term industry growth. Indian generic pharma giants are aggressively pivoting towards the global biosimilar market, particularly in the US and EU, with 118 biologics set to lose patent protection by 2034 creating significant market opportunities. The sector benefits from structural drivers including increasing global outsourcing, chronic therapies and speciality medicines.
